Eisai Hits First Milestone In Risk-sharing Alliance With Quintiles
This article was originally published in PharmAsia News
Executive Summary
Eisai’s lenvatinib achieved proof of concept for melanoma, and now Eisai steps back into the picture for Phase III.
You may also be interested in...
Quintiles And Eisai Collaborate To Develop Cancer Compounds
Moving beyond the traditional contract research organization model, Quintiles will collaborate with Eisai to perform 11 proof-of-concept trials on six oncology compounds in a deal announced Oct. 30
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.